All News

WIR.large_.jpg (keep)

RheumNow Podcast – The Future of JAKs (6.5.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Corona.COVID_.jpg

EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance

d Rachel Tate, DO

In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.

Read Article
mask.cough_.URI_.jpg

Preventing COVID - Masks, Meters and Eyewear

d Jack Cush, MD

A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.

The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients. 

Read Article
infx.pneumonia.jpg

Hydroxychloroquine Postexposure Prophylaxis for COVID-19 Fails

d Jack Cush, MD

NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.



Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.

Read Article

When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The Future of JAKs. Watch it here>> https://t.co/Ot483P99RB or listen to the Podcast on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>>https://t.co/1ImZzhb0mS

Links:

Dr. John Cush RheumNow ( View Tweet)

Tofacitinib shown to be effective (vs Placebo) in 225 Polyarticular JIA (included some ERA & PsA). with less flares (29 vs 53%) and higher JCR30 responses (71 vs 47%) @6mos #EULAR2020 #OP0281 https://t.co/3BnZeB4ROr https://t.co/4pTLbTtBdN

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC guidelines for Rx of Latent Tuberculosis; Preferred: A) 3 months of once-weekly INH plus rifapentine (3HP); B) 4 months of daily rifampin (4R); C) 3 months of daily INH plus rifampin (3HR) - Shorter, safer, effective with higher completion rates. https://t.co/a2iZczFTP2

Links:

Dr. John Cush RheumNow ( View Tweet)

Lancet has issued an almost retraction - an "Expression of Concern" alerting readers that many have voiced scientific concerns about the Lancet HCQ/CQ paper w/ more deaths. MORE DEATHS COULD HAVE BEEN FROM THE DRUGS OR THE DRUGS BEING USED IN SICKER PTS https://t.co/saoE32qpuF

Links:

Dr. John Cush RheumNow ( View Tweet)

Open label, uncontrolled study shows that background use of azathioprine (2mg/kg) in Pegloticase treated refractory gout patients was partly effective - 6/12 completed, 2 still on Rx, 2 PEG ineffective and 2 side effx #EULAR2020 #Gout Abst#THU0410 https://t.co/APZRPCQUFg https://t.co/Nfsq4QjyA5

Links:

Dr. John Cush RheumNow ( View Tweet)
Use of HCQ was not associated with development of ❤️Heart Failure in patients with RA. There was no statistically significant association between the cumulative dose of HCQ & HF. A good study from #MayoClinic. #EULAR2020 #eular20 https://t.co/yG03e0TAcV
Mario Pompermayer, MD pompermarioMD ( View Tweet)
ILD RA has more hospital admissions. Occurs in 14% of RA. Increased mortality. Serious complication of RA @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 OP0039 https://t.co/2N3tulzq3R

Links:

Janet Pope Janetbirdope ( View Tweet)

Nice surprise as IL23 Guselkumab works not only in PsA but axial PsA. Another Rx option also presented at @eular_org #EULAR2020 @CRASCRRheum @earlyarthritis https://t.co/dUqqagzbeC

Links:

Janet Pope Janetbirdope ( View Tweet)

Can machine learning/AI predict who will respond & get remission in RA prior to bDMARD? High dose steroids, older age high ESR long disease duration worse outcomes but not same for each drug. OP0023 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/oNXDVQbzMC
Janet Pope Janetbirdope ( View Tweet)
We're still poor at estimating the chance of remission with bDMARDs for individuals w RA - but maybe AI can help provide them with a personalised prediction of their chances of success? Remission predicted here w 57-73% accuracy. Korean national data OP0023 #EULAR2020 @RheumNow https://t.co/zNw3j5VZni
David Liew drdavidliew ( View Tweet)
Tocilizumab in GCA - three year data from GiACTA on steroid exposure and time to flare: - steroid-sparing benefit persists in both new-onset and relapsing disease - in avoiding flares, benefit for weekly dosing in both new-onset and relapsing disease OP0027 #EULAR2020 @RheumNow https://t.co/tGU6ayglHW
David Liew drdavidliew ( View Tweet)
"It's a brave new world!" Dr. Iain McInnes, president of #EULAR2020 discussing how the pandemic has created a "technological miracle" by bringing us all virtually together! @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Case control study to see if MTX is assoc with ILD in RA. Hypersensitivity pneumonitis pts were excluded. MTX use assoc with DELAYED onset of ILD so protective. let my RA pts use MTX if ILD or increased ILD risk ex male old +RF OP0036 @RheumNow @eular_org @CRASCRRheum #EULAR2020 https://t.co/NGM4t2OKTP
Janet Pope Janetbirdope ( View Tweet)
#EULAR2020 OP0026. RITAZAREM. Rituximab superior to Aza 2mg/kg in maintaining remission in relapsing AAV. Flare rate 13% vs 38%. Note Ritux schedule is 1g every 4 months (x 5 infusions out to month 20).

Patrick Kiely pkiely500 ( View Tweet)

Can we treat GPA /ANCA vasculitis without steroids? Apparently yes +RCT by P Merkel in #EULAR2020 plenary adding avacopan-blocks C5a. Gutsy move as No steroids in one arm! ?cost effectiveness but a breakthrough @RheumNow @eular_org @CRASCRRheum https://t.co/kp7IZOaHfP
Janet Pope Janetbirdope ( View Tweet)
×